Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Patriot Scientific Corporation v. Russell Fish
On November 22, 2006, the Company entered into a 120 day revolving line of credit with Holocom Networks (“Holocom”) for a maximum amount of $700,000. The line of credit is collateralized by the patents and trademarks of Holocom Networks. On the date of origin, the Company advanced Holocom Networks $350,000 and on December 5, 2006 the Company advanced $170,000 under terms of the agreement. The line carries a floating interest rate which is defined as 2% above the prime rate as announced by Bank of America. At November 30, 2006, the interest rate on the note was 10.25%.

The borrower is required to make minimum monthly payments on the line consisting of unpaid and accrued interest on the first day of the month following the initial advance.

At the time of this filing, the Company was in negotiations with representatives of the management and the investors of Holocom Networks that were expected to lead to the conversion of the Company’s cash advances under the line of credit to an equity investment in a reorganized Holocom entity. Further advances in connection with the Holocom investment are anticipated. The Company is accounting for its investment in debt at cost. The Company monitors the value of its investment in debt for indicators of impairment, including changes in market conditions and /or the operating results of its underlying investment that may result in the inability to recover the carrying value of the investment. The Company will record an impairment charge if and when it believes the investment has experienced a decline that is other than temporary. At November 30, 2006, the Company has determined that there is no impairment of its investment in debt securities.

Share
New Message
Please login to post a reply